Journal of gastroenterology and hepatology
-
J. Gastroenterol. Hepatol. · Jan 2009
Comparative StudySurface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.
To screen for serum biomarkers of HBV-related hepatocellular carcinoma (HCC) and HBV-related liver cirrhosis (LC) in an attempt to seek a new method for differential diagnosis of HCC and LC using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) techniques. ⋯ Special proteins/peptides of serum may differentiate HBV-related HCC and HBV-related LC, indicating that SELDI-TOF-MS may be useful to distinguish HCC from LC with the proper discriminant analytical method. SELDI peak 3892 may be a complementary diagnostic marker to positive AFP for HCC and a potential marker for the diagnosis of AFP-negative HCC as well.
-
J. Gastroenterol. Hepatol. · Dec 2008
Comparative StudyComparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM and CUPI.
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. However, there is no general consensus as to which staging system is the most reliable for predicting the survival of patients with HCC. The aims of this study were to compare commonly-used staging systems in a cohort of Chinese HCC patients undergoing curative resection. ⋯ For HCC patients undergoing curative resection, the TNM staging system (6th edition) proved the best for prognostic stratification and prognosis prediction.
-
J. Gastroenterol. Hepatol. · Dec 2008
Comparative StudyTaishotoyama Symposium Barriers to colorectal cancer screening: economics, capacity and adherence.
Colorectal cancer is the second leading cause of cancer death in the United States (U. S.). Fecal occult blood testing has been shown in randomized controlled trials to decrease mortality from colorectal cancer. ⋯ Patients who are given a choice of several strategies are less likely to adhere to any strategy than patients who are recommended a single strategy. To increase adherence to colorectal cancer screening it is recommended that the patient be instructed to undergo the test to which they are most likely to adhere. Future research should focus on interventions to improve patient adherence to screening, and on developing accurate tests that will achieve high levels of adherence.
-
J. Gastroenterol. Hepatol. · Dec 2008
Evaluation of EORTC QLQ-C30 questionnaire in patients undergoing in-hospital chemotherapy for gastrointestinal cancer in Japan.
There have been few studies in Japan of the utility of quality of life (QOL) questionnaires as an evaluation of chemotherapy for gastrointestinal (GI) cancer. The present study investigated whether QOL can be an indicator of the clinical benefit of chemotherapy, by analyzing the changes in the QOL scores of patients who underwent in-hospital chemotherapy for GI cancer. ⋯ Measurement of QOL score is a meaningful marker of the benefit of chemotherapy, other than tumor reduction. The NC group could be considered to have responded with improved QOL.
-
J. Gastroenterol. Hepatol. · Nov 2008
Comparative StudyClinical, biochemical, immunological and virological profiles of, and differential diagnosis between, patients with acute hepatitis B and chronic hepatitis B with acute flare.
In areas with high or intermediate endemicity for chronic hepatitis B virus (HBV) infection, it is difficult to distinguish acute hepatitis B (AHB) from chronic hepatitis B with an acute flare (CHB-AF) in patients whose prior history of HBV infection has been unknown. The present study aimed to screen laboratory parameters other than immunoglobulin M antibody to hepatitis B core antigen (IgM anti-HBc) to discriminate between the two conditions. ⋯ (i) There are significant differences with respect to clinical, biochemical, immunological and virological aspects between ASL-HB and CHB-AF. (ii) Of several diagnostic combinations, IgM anti-HBc jointing HBV-DNA is most effective and most practicable in distinguishing ASL-HB from CHB-AF. (iii) A low HBeAg level is more useful than negative HBeAg in differential diagnosis between ASL-HB and CHB-AF. (iv) In those patients with a high level of IgM anti-HBc, serum AFP level >10x upper reference limit could rule out a probability of ASL-HB.